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Abstract
Background: There is no biological or epidemiological data on the association between NOS3
promoter polymorphisms and prostate cancer. The polymorphisms in the promoter region of
NOS3 gene may be responsible for variations in the plasma NO, which may promote cancer
progression by providing a selective growth advantage to tumor cells by angiogenic stimulus and by
direct DNA damage.
Methods: This study aimed evaluating the NOS3 promoter polymorphisms by PCR-SSCP and
sequencing, associating genotypes and haplotypes with NOS3 expression levels through semi-
quantitative RT-PCR, and with PCA3 mRNA detection, a specific tumor biomarker, in the peripheral
blood of pre-surgical samples from 177 patients; 83 PCa and 94 BPH.
Results: Three novel SNPs were identified -764A>G, -714G>T and -649G>A in the NOS3 gene
promoter region, which together with the -786T>C generated four haplotypes (N, T, C, A). NOS3
gene expression levels were affected by the -786T>C polymorphism, and there was a 2-fold
increase in NOS3 levels favored by the incorporation of each C allele. NOS3 levels higher than 80%
of the constitutive gene expression level (B2M) presented a 4-fold increase in PCa occurrence.
Conclusion: The -786T>C polymorphism was the most important promoter alteration of the
NOS3 gene that may affect the PCa progression, but not its occurrence, and the incorporation of
the C allele is associated with increased levels of NOS3 transcripts. The NOS3 transcript levels
presented a bimodal behavior in tumor development and may be used as a biomarker together with
the PCA3 marker for molecular staging of the prostate cancer.
Background
Enzymes responsible for nitric oxide (NO) synthesis con-
stitute a family with at least three distinct isoforms, induc-
ible, neuronal and endothelial [1]. The nitric oxide
synthase 3 (NOS3) is located at the 7q35-q36 chromo-
some locus and the characterization of the 5'-flanking
genomic region indicates that the NOS3  promoter is
'TATA-less'. This feature has been described for genes such
as housekeeping genes and is usually associated with mul-
tiple transcription start sites. The NO synthase mRNA
does not correspond to these criteria and the presence of
specific potential transcription factor binding sites in the
promoter could account for the cell specificity of its tran-
scription [2].
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The NOS3 seems to have an important role in vascular
development, maintenance of the vascular tone and
tumor growth in human prostate cancer (PCa) [3]. The
net effects of NO depend on its available concentration,
target cell, and interactions with reactive oxygen species
(ROS), metal ions, and proteins [4,5].
The tumor-associated NO production may promote can-
cer progression by providing a selective growth advantage
to tumor cells, by the angiogenic stimulus [6,7] and by the
raise on mutations due to direct action of free radicals in
DNA [8], and may also stimulate hyperplasia in normal
tissue [8-10].
Genetic polymorphisms in the promoter region of NOS3
gene (Figure 1) may be responsible for variations in the
genetic control of plasma NO [11,12]. Although the pro-
moter region is not part of the mRNA, it is directly related
to the exons, and might be intervening at gene expression,
decreasing or increasing it. Moreover, mutation points
present in 5'- flanking region may confer a higher instabil-
ity to the mRNA. To date ten variant NOS3 alleles have
been identified in this region, these are, or may be, associ-
ated with decreased enzyme activity [13].
In this study, we have performed a specific analysis of a
236 base pair (bp) fragment of the NOS3 gene promoter
region flanking the polymorphisms -786T>C and -
690C>T, through DNA conformational assays (SSCP –
single strand conformation polymorphism) and sequenc-
ing, determining genotypes and haplotypes, and estimat-
ing their possible association with PCa and benign
prostatic hyperplasia (BPH) diseases. Three novel single
nucleotide polymorphisms (SNPs) were characterized.
Additionally, we have evaluated the effect of these five
NOS3 SNPs on the mRNA expression levels of the periph-
eral blood of PCa and BPH patients, and their association
with circulating tumor cells in the blood.
Methods
Patients, sample collection and preparation
This work was developed at the Laboratory of Nanobio-
technology of the Federal University of Uberlandia (UFU)
together with the Urology Service of the University Clin-
ics' Hospital. All the peripheral blood samples were
Nucleotide sequence of NOS3 gene promoter Figure 1
Nucleotide sequence of NOS3 gene promoter. Potencial cis-regulatory sequences are indicated in white boxes. The 
translation iniciation codon ATG is indicated in a black box. Underlined-bold nucleotides are indicating the 13 point mutations 
described for the promoter region. The three novel mutations and the 236-bp amplified fragment are highlighted in gray boxes.BMC Cancer 2008, 8:273 http://www.biomedcentral.com/1471-2407/8/273
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obtained from patients that live in Uberlandia – MG (Bra-
zil) and were enrolled during 2003 and 2004. The ethnic
background was not recorded since the Brazilian popula-
tion is highly heterogeneous and miscegenated, so it can-
not be determined. The investigation was approved by the
UFU Research Ethics Committee under the number 005/
2001. Peripheral blood samples were collected before sur-
gery in a vacutainer™ tube containing K2 EDTA 7.2 mg,
and maintained at 4°C. To search for possible mutations
in the promoter region of the NOS3 gene, we have per-
formed the PCR-SSCP analysis in blood samples from 177
patients, which were grouped into two classes: 83 PCa
(mean age, 69 years; range, 50 to 87 years) and 94 BPH
(mean age, 68 years; range, 49 to 87 years), according to
histological classification of tissues. BPH patients were
submitted to TURP, except five patients that have under-
gone open prostatectomy. All PCa patients were submit-
ted to radical prostatectomy, and were selected by using
the following criteria: negative X-rays and bone scan anal-
yses, and rectal examination compatible with organ con-
fined cancer. DNA was extracted from leukocytes
according to protocol previously published [14]. The
mRNA was isolated by the Guanidine Isothiocyanate
extraction method [15] with minor modifications. DNA
and mRNA concentrations and quality were obtained by
using the spectrophotometric absorbance readings at 260
and 280 nm.
Amplification and genotyping of the -786T>C 
polymorphism
The presence of the -786T>C polymorphism in the 5'-
flanking region of the NOS3 gene was determined by PCR
amplification with the primers 5'-ATG CTG CCA CCA
GGG CAT CA- 3' and 3'-GTC CTT GAC TCT GAC ATT
AGG G- 5' [16]. A volume of 30 μL was used for each PCR
reaction, which contained 5 ρmoles of each primer, 200
μM of each dNTP (desoxyribonucleotide triphosphate),
1.5 mmol/L MgCl2, 50 mmol/L KCl, 10 mmol/L Tris-HCl
at pH 8.3 and 1 U Taq DNA polymerase (Phoneutria)
with 4 μL of genomic DNA. The conditions of amplifica-
tion were denaturing at 95°C-5 min, 35 cycles at 94°C-1
min, 62°C-1 min, 72°C-1 min, and a finally termination
at 72°C-10 min. The amplified fragments were separated
on 1.5% agarose gel electrophoresis and stained with
ethidium bromide.
PCR-SSCP analysis
A PCR-SSCP analysis, described elsewhere [17], was per-
formed to detect mutations within the NOS3 promoter
region. Two microliters of PCR products were mixed with
18 μL of a low ionic strength buffer (10% sucrose, 0.01%
bromophenol blue, and 0.01% xylene cyanol) and heat-
denatured for 10 min at 97°C. Products were separated on
15% polyacrylamide gel electrophoresis (49:1 – acryla-
mide:bisacrylamide) with 200 volts for 19 hours at room
temperature, and detected by silver nitrate staining
[18,19] with minor modifications.
Purification of SSCP fragment bands and sequencing
During genotyping of the -786T>C polymorphism of the
NOS3 gene promoter region, three novel SNPs have been
discovered [-764A>G, GenBank: RefSeq NM_EF042808/-
714G>T, GenBank: RefSeq NM_EF042809/-649G>A,
GenBank: RefSeq NM_EF042810]. Additionally, the two
SNPs previously described [-786T>C, GenBank: RefSeq
NM_2070744/-690C>T, GenBank: RefSeq NM_3918225]
were also characterized. Seven SSCP conformations were
observed in the polyacrylamide gel electrophoresis (Fig-
ure 2), although only three conformations were expected.
Each DNA fragment band originated from the PCR-SSCP
technique was scrapped and individually reamplified
using the same PCR reaction condition.
The purification of reamplified fragments was performed
by DNA precipitation with ammonium acetate (7.5 M)
and the pellet was ressuspended in 10 μL of water. DNA
concentration and quality were obtained by using the
spectrophotometric absorbance readings at 260 and 280
nm.
The purified products were submitted to a capillary
sequencer (MegaBace 1000), using the DYEnamic ET Dye
Terminator Cycle Sequencing kit (GE Healthcare). Three
sequencing reactions had been carried for each fragment
and injected twice to minimize sequencing artifacts.
Sequences were processed and edited in the software
DNASTAR Lasergene – SeqMan and EditSeq – (version
7.0, 2006). Sequences were aligned with the correspond-
ing NOS3 sequence (GenBank: NM_348236) using the
MegAlign procedure (DNASTAR Lasergene). The consen-
sus sequences for each SSCP fragment band was estab-
lished and comparisons were performed based on the
original NOS3 gene sequence.
RNA extraction and RT-PCR
Two microgramas of total RNA from blood, 10 U of
RNase inhibitor (Invitrogen), 40 U of the Murine Moloney
Leukemia Virus Reverse Transcriptase (MMLV-RT) (Amer-
sham Biosciences), 1X MMLV-RT Buffer, 200 μM of each
dNTP and 6 μM of hexamer random primers were incu-
bated at 37°C for 1 hour and heated at 95°C-5 min. The
20 μL final volume of each reaction was completed with
DEPC (diethylpyrocarbonate)-treated water. For normali-
zation of amplification reactions, the internal positive
control gene, the constitutive B2M gene (B2M: 5' -AGC
AGA GAA TGG AAA GTC AAA- 3' and 5' -TGT TGA TGT
TGG ATA AGA GAA- 3'), generating a 534-bp fragment,
was used to validate reactions and to further characterize
RNA quality of each sample.BMC Cancer 2008, 8:273 http://www.biomedcentral.com/1471-2407/8/273
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Nested RT-PCR for the PCA3 transcript detection
A sensitive nested PCR assay for the detection of PCA3
mRNA was performed as previously reported [20] with
minor modifications. A total of 137 patients were ana-
lyzed for the expression of circulating tumor cells in the
peripheral blood, as evidenced by the PCA3  tumor
biomarker positivity (Figure 3A and 3B).
Semi-quantitative RT-PCR of the NOS3 gene
A representative sample of the genotyped population was
selected, consisting of 38 patients (18 PCa and 20 BPH
cases), and were analyzed in three replicates for the NOS3
mRNA relative expression levels. PCR reactions consisted
of: 4 μL of cDNA, 1 U of Platinum Taq DNA Polymerase
(Invitrogen), 50 mmol/L KCl, 10 mmol/L Tris-HCl at pH
8.3, 200 μM of each dNTP, 8 ρmoles of each oligonucle-
otide, 2 mmol/L MgCl2. The reaction was incubated for 48
PCR-SSCP analysis Figure 2
PCR-SSCP analysis. 15% polyacrylamide gel electrophoresis (49:1 acrylamide:bisacrylamide) with silver staining, evidencing 
the seven genotypic conformations and their chromosome models with four possible haplotypes, constructed based on the five 
NOS3 promoter polymorphisms investigated.BMC Cancer 2008, 8:273 http://www.biomedcentral.com/1471-2407/8/273
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cycles at 94°C-40 s, 55°C-40 s, 72°C-50 s, preceded by an
initial denaturation at 95°C-2 min and a final extension
cycle at 72°C-10 min. The designed primers sequence for
the NOS3 were: sense 5' -CCT CAG GTT CTG TGT GTT
CG- 3' and antisense 5'- GAT CAG ACCT GGC AGC AAC
T- 3', generating a 322-bp fragment. The B2M constitutive
gene was concomitantly amplified in the same reaction as
described before.
Densitometric readings to estimate relative gene 
expression levels
The amplicons obtained for both NOS3 and B2M genes
were analyzed and quantified according to their agarose
signal intensities by using the ImageMaster VDS Software
program version 2.0 (Amersham Biosciences). The densi-
tometric readings were normalized by using the target
NOS3 mRNA:B2M mRNA ratio and relative levels were
estimated for each sample (Figure 3C and 3D).
Statistical analysis
Chi-square analyses were performed to compare geno-
typic and haplotypic frequencies for the average of clinical
parameters, such as: age, PSA serum levels. Multiple
regression analysis and Pearsons' correlations were used
to verify the association among genotypes, PCA3 detec-
tion and clinical data. The Shapiro-Wilk test was used to
verify normality of the relative levels of NOS3 gene expres-
sion, and mean comparisons of the mRNA relative levels
were performed between PCa and BPH patients' groups
through the Mann-Whitney test. Probability levels below
5% (p < 0.05) were considered significant. A cut-off value
was determined for the NOS3 transcript relative levels and
the OR were estimated to verify the chance of PCa occur-
rence in the presence of high concentrations of NOS3
transcripts. Pearsons' correlation analysis was performed
among NOS3 relative expression levels of PCa and BPH
patients in association with patients' age, serum PSA lev-
els, the TNM adenocarcinoma histopathological staging,
gleason score and polymorphisms.
Results
Molecular characterization of the SSCP conformations 
and the haplotypes models of the promoter region
Sequences of the SSCP electrophoretic bands were
obtained and the consensus sequence was established
(Figure 4). Sequence alignments were compared with the
original sequence of the NOS3  gene [GenBank:
NM348236], and all SNPs were positioned in the
sequence, and their mutation classifications were assigned
(Table 1).
Based on consensus sequences, it was possible to con-
struct four specific haplotypes N (-786T>C; -690A>G; -
649G>A), C (-786T>C; -714G>T; -690C>T), A (-786 T>C;
-764A>G; -690C>T) and T (no mutations). Chromosome
models were also generated to explain the seven SSCP
electrophoretic conformations: TT (no mutations), TC (-
786T>C + [=], -714G>T + [=], -690C>T + [=]), CC (-
786T>C + -786T>C, -714G>T + -714G>T, -690C>T + -
690C>T), TA (-786T>C + [=], -764A>G + [=], -690C>T +
[=]), AA (-786T>C + -786T>C, -764A>G + -764A>G, -
690C>T + -690C>T), CA (-786T>C + -786T>C, -764A>G +
[=], -714G>T + [=], -690C>T + -690C>T and TN (-786T>C
+ [=], -690C>T + [=], -649G>A + [=]) (Figure 2).
SSCP conformations and haplotypic frequencies of the five 
mutations in promoter region of NOS3 gene
Table 2 shows SSCP conformations with their respective
genotypes and haplotypic frequencies for all five charac-
terized polymorphisms performed in 177 patients, from
which 83 (46.9%) were histologically diagnosed as PCa
and 94 (53.1%) as BPH. The -786T>C polymorphism pre-
sented the highest frequencies in both patients' groups,
with higher frequencies for the TT and TC SSCP conforma-
tions. For the PCa group, all the other conformations (TA,
CA, TN, and AA) did not present frequencies higher than
6%; however, the same four genotypic conformations pre-
sented higher frequencies in the BPH group, with 13.8%
(13 out of 94) for the TA SSCP conformation, and 9.6%
(9 out of 94) for the CA SSCP conformation.
Nested RT-PCR for the PCA3 and B2M gene expression anal- ysis Figure 3
Nested RT-PCR for the PCA3 and B2M gene expres-
sion analysis. A) Lanes 1 to 4: amplifications for the PCA3 
gene, where sample pairs 1 and 2, 3 and 4, correspond to 
two RNA extraction replicates for each patient. The detec-
tion of the expected 277-bp PCA3 fragment evidences the 
presence of circulating tumor cells. Lane M: 100-bp size 
marker. B) Lanes 1 to 4: amplifications for the B2M gene 
(534-bp). Semi-quantitative RT-PCR for the NOS3 and B2M 
gene expression analysis. The 322-bp and 534-bp fragments 
correspond to the NOS3 and B2M genes, respectively. Lane 
M: 100-bp size marker. Lanes 1 to 10 represent individual 
patients, where (C) represent BPH patients' profile, and (D) 
the PCa patients' profile.BMC Cancer 2008, 8:273 http://www.biomedcentral.com/1471-2407/8/273
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Sequences alignment using DNASTAR Lasergene (SEQMAN and EDITSEQ), version 7.0 (2006) Figure 4
Sequences alignment using DNASTAR Lasergene (SEQMAN and EDITSEQ), version 7.0 (2006). The point 
mutations are represented in a black box. A) -786T>C polymorphism. B) -764A>G polymorphism. C) -714G>T polymor-
phism. D) -690C>T polymorphism. E) -649G>A. Coding DNA reference sequence of promoter NOS3 gene [GenBank: 
NM_348236]. SSCP Conformations: AA, CC, TN, TA and TT.BMC Cancer 2008, 8:273 http://www.biomedcentral.com/1471-2407/8/273
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No significant differences for SSCP conformations fre-
quencies between patients' groups were observed (p =
0.10). However, the comparison of the SSCP conforma-
tions frequencies within the PCa patients (p = 0.0082)
and within BPH patients (p = 0.0011) were significant dif-
ferent.
There was no haplotypic frequencies difference between
groups (p > 0.05). However, inspection of haplotypes
revealed that the C (-786T>C; -714G>T; -690C>T) and T
(no mutation) haplotype was the most common one in
both patients' groups. One rare haplotype N (-786T>C; -
690A>G; -649G>A) has been observed in PCa patients
(1.2%). Although not significant, the haplotype A (-786
T>C; -764A>G; -690C>T) was more frequent in BPH
patients (12%) than in PCa (8%). Both haplotypes and
SSCP genotypic conformation frequencies distribution
were in Hardy-Weinberg equilibrium.
The estimated chance for cancer occurrence, considering
the seven SSCP genotypic conformations among groups
(PCa and BPH), were: TT + TC + CC + CA + AA versus (vrs)
TA (odds ratio (OR) = 3.13, CI95%, 0.98 – 10.01), TT + CA
vrs TA (OR= 2.99, CI95%, 0.89 – 10.05), CC vrs CA + TA
(OR= 3.38, CI95%, 1.00 – 11.37), TT vrs CA + TA (OR=
3.10, CI95%, 1.25 – 7.72). All combinations of SSCP con-
formations were tested for the OR, but only the most sig-
nificant ones were demonstrated. It was observed a 3.38-
fold higher chance of having cancer when the CC SSCP
conformation is considered in relation to CA + TA. A 3.10-
fold higher chance of having cancer was obtained for the
TT SSCP conformation in relation to CA + TA. The TT + TC
+ CC + CA + AA vrs TA and TT + CA vrs TA associations
were close to significance (p < 0.10), and presented a rel-
ative risk of 3.13 and 2.99-fold higher chance of having
cancer, respectively.
Table 3 shows the estimated chance for cancer occurrence,
considering haplotypes and their number of copies
between groups (PCa and BPH), and no significant ORs
were obtained. The sample size was quite small for some
haplotypes, but we presented the true haplotypic frequen-
cies of copy numbers in the population investigated for
the polymorphisms within the 236-bp region, and
although the haplotypes were not significantly associated
with prostate cancer, this is the first description of such
variations in the NOS3 promoter.
In agreement with the Kruskal-Wallis test, significant dif-
ferences between patients' groups for mean prostate spe-
cific antigen (PSA) were observed (p = 0.0048). Pearsons'
correlation coefficients for genotypes vrs PSA (p = 0.02),
genotypes vrs gleason score (p = 0.0195), age vrs PSA (p =
0.0412), age vrs gleason score (p = 0.0421), gleason score
vrs Tumor-Node-Metastasis (TNM) score (p = 0.0021) and
PSA vrs TNM score (p = 0.0189) within the PCa patients
were significantly different. No significant differences
among BPH patients were observed (Table 2).
Analysis of the PCA3 transcript detection and association 
with polymorphisms
The prostate cancer antigen 3 (PCA3) transcript detection
(Figure 3A) was performed in 149 patients (149 out of
177), from which 109 (73.2%) were negative and 40
(26.8%) were positive. Among PCA3  positive patients,
62.5% (25 out of 40) were histologically diagnosed as
PCa and 37.5% (15 out of 40) as BPH. Among PCA3 neg-
ative patients, 42.2% (46 out of 109) were PCa and 57.8%
(63 out of 109) were BPH (Table 4). Although patients'
Table 1: NOS3 gene promoter point mutations according to site and type.
Position within 
promoter region
Position within 236-bp 
NOS3 fragment
Mutation classification Nucleotide base codes 
(IUPAC)
dbSNP ID (GenBank)
- 1468 -- Transition W not deposited
- 1038 -- Transversion S NM_2243311
- 976 -- Transversion V NM_2243311
- 934 -- Transversion S NM_2243311
- 922 -- Transition R NM_2243311
- 896 -- Transition Y NM_2243311
- 857 -- Transition Y NM_3918161
- 786 35 Transition Y NM_2070744
() - 764 57 Transition V NM_EF042808
- 736 83 Insertion N NM_35886277
() - 714 107 Transversion K NM_EF042809
- 690 131 Transition Y NM_3918225
() - 649 172 Transition V NM_EF042810
() novel single nucleotide polymorphism
(--) polymorphism located outside the 236-bp
(W) A or T; (S)G or C; (V)A or C ou G; (R)A or G; (Y)C or T; (N)any base; (K)G or T.B
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Table 2: SSCP conformation and haplotypic frequencies, clinical parameters and laboratory data of the NOS3 gene in peripheral blood of patients with prostate cancer and benign prostatic 
hyperplasia.
PCa (N = 83) BPH (N = 94)
SSCP 
Confor
mation
Genotypes
(a)
N (%) * Age * PSA
(ng/ml)
* TNM 
score
* Gleason 
score
% positive 
PCA3
*
[NOS3]
% (N) * Age * PSA
(ng/ml)
% positive
PCA3
*
[NOS3]
TN c. [-786T>C] + [=]
c. [-690C>T] + [=]
c. [-649G>A] + [=]
1 (1.2) 77 101.0 -- 9 0
(0 out of 1)
- -0- -- -- -- -
CC c. [-786T>C] + [-786T>C]
c. [-714G>T] + [-714G>T]
c. [-690C>T] + [-690C>T]
9 (10.8) 67.5 (7.3) 41.4 (78.8) 1 8 42.9
(3 out of 7)
-- 8 (8.5) 66.8 (7.8) 15.3 (11.7) 12.5
(1 out of 8)
0.5 (0.2)
TT No mutations 30 (36.2) 68.5 (8.4) 24.0 (28.4) 2 7 28.0
(7 out of 25)
1.1 (1.8) 29 (30.9) 66.7 (9.2) 9.8 (10.3) 18.5
(5 out of 27)
0.5 (0.3)
TC c. [-786T>C] + [=]
c. [-714G>T] + [=]
c. [-690C>T] + [=]
32 (38.6) 69.7 (7.8) 17.3 (18.7) 1 6 35.7
(10 out of 
28)
1.1 (1.5) 35 (37.2) 68.9 (8.4) 11.9 (12.3) 15.4
(4 out of 26)
0.6 (0.4)
TA c. [-786T>C] + [=]
c. [-764A>G] + [=]
c. [-690C>T] + [=]
4 (4.8) 64.5 (10.0) 11.6 (7.2) 2 6 66.7
(2 out of 3)
4.7 (4.3) 13 (13.8) 67.2 (10.1) 9.5 (7.3) 20.0
(2 out of 10)
0.4 (0.3)
CA c. [-764A>G] + [=]
c. [-714G>T] + [=]
c. [-786T>C] + [-786T>C]
c. [-690C>T] + [-690C>T]
5 (6.0) 63.8 (7.4) 9.4 (3.4) 1 6 40.0
(2 out of 5)
6.0 (0.3) 9 (9.6) 66.7 (8.6) 11.9 (7.9) 42.9
(3 out of 7)
0,6
AA c. [-786T>C] + [-786T>C]
c. [-764A>G] + [-764A>G]
c. [-690C>T] + [-690C>T]
2 (2.4) 70.5 (7.8) 12.1 (12.1) -- 7 50.0
(1 out of 2)
- -0- -- -- -- -
Total 83 43.1
(25 out of 
71)
94 19.0
(15 out of 
78)
p(1) p = 0.0082 p = 0.0011
p(2) p = 0.10
Haplotypes % * Age * PSA
(ng/ml)
* TNM 
score
* Gleason 
score
% positive
PCA3
*
[NOS3]
%*  A g e *  P S A
(ng/ml)
% positive
PCA3
*
[NOS3]
N c. [-786T>C; -690A>G; -
649G>A]
1.0 77 101.0 -- 9 0.0 -- 0 -- -- 0
T No mutations 58.0 69.9 38.5 1 6 56.0 1.1 56.0 67.6 10.4 53.2 0.4
C c. [-786T>C; -714G>T; -
690C>T]
33.0 66.7 22.7 1 7 32.0 1.1 32.0 67.5 11.0 30.1 0.3
A c. [-786T>C; -764A>G; -
690C>T]
8.0 66.3 11.0 2 6 12.0 2.6 12.0 66.9 10.7 16.7 0.2
Total 100.0 100.0 (25) 100.0 100.0 (15)
() representative sampling of the population; (*) mean (± SD); (--) inapplicable data
(1) Comparison (genotypes) in the groups with probability levels obtained by chi-square tests
(2) Comparison (genotypes) between groups with probability levels obtained by Kruskal-Wallis test
(a) Genotypes correspond to the promoter NOS3 polymorphismsBMC Cancer 2008, 8:273 http://www.biomedcentral.com/1471-2407/8/273
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histological classification (PCa and BPH) were carefully
analyzed, it is possible that transurethral resection of pros-
tate (TURP) biopsies of BPH patients have been misdiag-
nosed, once biopsy procedures may not have reached
tumor specific sites.
PCA3  positivity in all SSCP conformations and haplo-
types were also shown in Table 4. It was expected a higher
frequency of PCA3 positivity in the PCa group and a lower
frequency of positivity in the BPH group, as observed,
although not significant. It is interesting to mention that
the PCA3 positivity in the PCa group for the TC + CC con-
formations was 2.6 times higher than the frequency
observed in the BPH group (32.5% vrs 12.5%, P = 0.02).
On the other hand, CC + TC conformations frequencies
were not significantly different between patients' groups
(PCa = 20.2% vrs BPH = 26.6%) within the negative PCA3
detection class (Table 4). The TA + CA conformations pre-
sented significantly higher frequencies in the BPH (11%)
than in the PCa group (3.6%) within the negative PCA3
class (P = 0.03).
In the overall, the PCA3 clinical parameters for PCa cell
detection in the peripheral blood were: 35.0% of sensitiv-
ity (25 out of 71), and 81.0% of specificity (63 out of 78);
however, it is important to emphasize that a positive
result for PCa patients is not an indication of metastasis,
and the PCA3 detection in BPH patients may indicate that
they may have been misdiagnosed.
For the negative PCA3 detection (Table 4), all genotypic
frequencies were higher among BPH patients, except for
the TN SSCP conformation that presented only a negative
result for one PCa patient.
Considering the haplotypic frequencies for the positive
and negative PCA3 detection classes, there were no differ-
ences between patients' groups. However, the T haplotype
(no mutations) was the most frequent one followed by
the C (-786T>C; -714G>T; -690C>T) and A (-786 T>C; -
764A>G; -690C>T) haplotypes. The A haplotype was
more frequent in BPH than in PCa patients, for both pos-
itive and negative PCA3 classes, although it was not signif-
icant.
Analysis of the NOS3 gene expression levels in association 
with polymorphisms
The semi-quantitative analyses of the NOS3 transcript lev-
els and their association with polymorphisms and haplo-
types were performed by selecting a representative sample
of the population based on the genotypic frequencies and
clinical parameters. The 38 patients used in this study pre-
sented the same genotypic frequencies and average values
for the clinical parameters observed in the patients' popu-
lation (177 patients).
The NOS3 relative levels related to the beta-2-microglob-
ulin (B2M) in the peripheral blood did not follow a nor-
mal distribution (n = 38, p = 0.33). Although not
significant, the mean NOS3 relative levels was four times
higher in PCa in relation to BPH patients (ratio NOS3
mRNA/B2M mRNA: 2.23 and 0.50, respectively) (Figure
3B).
A cut-off value for the relative levels of NOS3 transcripts
were established based on the maximum average levels
observed for the BPH group. The cut-off value for negative
results was below 0.8 for the NOS3 mRNA/B2M mRNA
ratio, which means 80% of the observed value for the B2M
transcript levels. Considering the cut-off value, it was
Table 3: NOS3 gene promoter haplotypes, number of copies, and prostate cancer risk.
Haplotypesa
(SSCP Conformation)
Units Zero Copies One Copy p-Value Two copies p-Value
No mutations
(T)
Controls/cases 17/16 48/36 0.73 29/30 1.0
OR (95% CI) 1.00 (ref) 0.80 (0.36 – 1.79) 1.10 (0.47 – 2.58)
[-786T>C; -714G>T; -690C>T]
(C)
Controls/cases 42/36 44/37 0.92 8/9 0.81
OR (95% CI) 1.00 (ref) 0.98 (0.52–1.83) 1.31 (0.46 – 3.76)
[-786T>C; -764A>G; -690C>T]
(A)
Controls/cases 72/71 22/11 0.13 0/2 --
OR (95% CI) 1.00 (ref) 0.51 (0.23 – 1.12) --
[-786T>C; -690A>G; -649G>A]b
(N)
Controls/cases 94/82 0/1 -- 0/0 --
OR (95% CI) 1.00 (ref) -- --
(a) Alleles listed for dbSNP ID (GenBank) in 5' to 3' order: NM_2070744, NM_EF042808, NM_EF042809, NM_3918225, NM_EF042810.
(b) Haplotype that appear only once between groups (PCa and BPH).
CI: confidence interval/OR: odds ratio
(--) inapplicable dataBMC Cancer 2008, 8:273 http://www.biomedcentral.com/1471-2407/8/273
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observed a 4.0-fold higher chance (CI95%, 0.95 – 16.77; p
= 0.12) of having cancer when the NOS3 expression levels
were equal or higher than 0.8.
Among PCa patients, only the Pearsons' correlation coef-
ficients obtained among the NOS3 gene expression and
PCA3 data (p = 0.038) were significant. For BPH patients,
the NOS3 levels, serum PSA, patients' age on diagnosis
and  PCA3  detection were not correlated among each
other. However, the average NOS3  levels presented a
bimodal behavior in PCa patients classified according to
their tumor stages, with higher levels in the pT2 stage (Fig-
ure 5A).
No significant differences among NOS3 gene expression
levels and haplotypes were observed between groups
(Table 2). However, there was a significant association of
NOS3  genotypes and gene expression levels for PCa
patients (p = 0.011), but not within the BPH group. It was
observed increased levels of NOS3 transcripts within the
PCa group, especially for patients with TA and CA SSCP
conformations, with NOS3 mRNA/B2M mRNA ratios of
4.7 and 6.0, respectively.
The average NOS3 levels were 3.52-fold higher in PCA3
positive patients (NOS3 mRNA/B2M mRNA = 3.17) in
comparison to the average observed in PCA3  negative
patients (NOS3 mRNA/B2M mRNA = 0.90), although not
significant, due to the low number of PCA3 positive sam-
ples analyzed.
Analysis of the NOS3 expression levels across the -786T>C
polymorphism on all patients showed a linear behavior
with an additive component for each C allele incorpo-
rated into the genotype, with higher levels (2.27)
observed for the (-786T>C + -786T>C) mutant
homozygous patients, followed by medium levels (1.47)
Table 4: PCA3 mRNA detection in the peripheral blood of PCa and BPH patients across genotypic SSCP conformations and their 
haplotypes.
Positive PCA3 mRNA
(N = 40)
Negative PCA3 mRNA
(N = 109)
SSCP Genotypes PCa
N (%)
BPH
N (%)
Total PCa
N (%)
BPH
N (%)
Total
TN [-786T>C] + [=]
[-690C>T] + [=]
[-649G>A] + [=]
000/0 1
(0.9)
0 1/109
(0.9)
CC [-786T>C] + [-786T>C]
[-714G>T] + [-714G>T]
[-690C>T] + [-690C>T]
3
(7.5)
1
(2.5)
4/40
(10)
4
(3.7)
7
(6.4)
11/109
(10.1)
TT No mutations 7
(17.5)
5
(12.5)
12/40
(30)
18
(16.5)
22
(20.2)
40/109
(36.7)
TC [-786T>C] + [=]
[-714G>T] + [=]
[-690C>T] + [=]
10
(25)
4
(10)
14/40
(35)
18
(16.5)
22
(20.2)
40/109
(36.7)
TA [-786T>C] + [=]
[-764A>G] + [=]
[-690C>T] + [=]
2
(5)
2
(5)
4/40
(10)
1
(0.9)
8
(7.3)
9/109
(8.3)
CA [-764A>G] + [=]
[-714G>T] + [=]
[-786T>C] + [-786T>C]
[-690C>T] + [-690C>T]
2
(5)
3
(7.5)
5/40
(12.5)
3
(2.7)
4
(3.7)
7/109
(6.4)
AA [-786T>C] + [-786T>C]
[-764A>G] + [-764A>G]
[-690C>T] + [-690C>T]
1
(2.5)
0 1/40
(2.5)
1
(0.9)
0 1/109
(0.9)
Total 25/40
(62.5)
15/40
(37.5)
40/149
(26.8)
46/109
(42.2)
63/109
(57.8)
109/149
SSCP Haplotypes PCa
%
BPH
%
PCa
%
BPH
%
N [-786T>C; -690A>G; -649G>A] 0 0 1 0
T No mutations 56 53 61 59
C [-786T>C; -714G>T; -690C>T] 32 30 31 32
A [-786T>C; -764A>G; -690C>T] 12 17 7 9
* PCA3 gene expression (PCa = 71/BPH = 78)BMC Cancer 2008, 8:273 http://www.biomedcentral.com/1471-2407/8/273
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Graphics representations Figure 5
Graphics representations. A) The average NOS3 relative levels of PCa patients classified according to tumor stages and a 
predicted tendency line. B) Regression analysis for the average NOS3 relative levels in association with the -786T>C polymor-
phism genotypes for all patients and for the group of patients with positive PCA3 detection.BMC Cancer 2008, 8:273 http://www.biomedcentral.com/1471-2407/8/273
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for the (-786T>C + [=]) heterozygous and lower levels
(0.67) for normal homozygous patients (Figure 5B).
Similarly, the NOS3 levels within the positive PCA3 class
(grouping BPH and PCa patients) presented a linear
behavior considering the -786T>C polymorphism, with
higher levels (3.1) for the (-786T>C + -786T>C) mutant
homozygous patients, followed by medium levels (2.3)
for the (-786T>C + [=]) heterozygous and lower levels
(1.5) for normal homozygous patients (Figure 5B).
Discussion
During the genotyping of the -786T>C polymorphism of
the NOS3 promoter [16], we have discovered and charac-
terized three novel mutations [-764A>G, GenBank:
NM_EF042808/-714G>T, GenBank: NM_EF042809/-
649G>A, GenBank: NM_EF042810] in the PCa and BPH
patients. The association between these three mutations
together with two SNPs previously described [-786T>C,
GenBank: NM_2070744/-690C>T, GenBank:
NM_3918225] and prostate cancer was further examined.
The five polymorphisms have generated seven genotypic
profiles in the polymerase chain reaction-single-strand
conformation polymorphism (PCR-SSCP) gel electro-
phoresis and four haplotypes, suggesting that some muta-
tions are closely linked; therefore, they have evolved
together, originating a restricted number of haplotypes. It
is interesting to observe that when the -786T>C mutation
was present at least two other mutations were linked. But,
when the normal -786T allele was present, no additional
polymorphisms were detected, explaining the four possi-
ble haplotypes.
This is the first publication that associates the promoter
polymorphisms of the NOS3 gene with prostate cancer
risk; however, other polymorphisms, such as the 894G>T
(Glu298Asp) and the intron 4 have also been evaluated
[21-24].
The possibility of linkage between the two previously
described NOS3 gene polymorphisms and the promoter
polymorphisms has not been investigated, and some con-
troversies may occur in the literature probably due to the
incorrect population stratification based on genotyping,
which could be generating linkage disequilibrium among
polymorphisms in the population that may present a
functional association with the NOS3  expression and
activity. However, there is an evidence that the 894G>T
polymorphism had no influence on NOS3 transcriptional
levels, but it was associated with PCA3 detection [24].
The strategy of determining genotypic conformations of
the NOS3 promoter region through the SSCP technique
demonstrated to be very effective in classifying all
patients. The significant relative risks of cancer occurrence
related to CC and TT SSCP conformation (3.38 and 3.10,
respectively) in comparison to TA + CA suggest that the -
786T>C polymorphism is the most important promoter
alteration that may affect the PCa progression. It is also
important to observe that patients with the CC SSCP con-
formation, in both PCa and BPH groups, presented the
highest serum PSA averages.
In the present work, there is a good evidence that the -
786T>C polymorphism affects the NOS3 expression, with
the (-786T>C + -786T>C) mutant homozygous condition
presenting the highest levels of NOS3 transcripts, and act-
ing in an additive manner, as the C allele is incorporated
into the genotype. This was also observed within the pos-
itive  PCA3  detection class, although positive PCA3
patients present higher levels of NOS3 transcripts. How-
ever, some authors have associated the (-786T>C + -
786T>C) genotype with low levels of NOS3 mRNA, which
would be contributing to a higher risk of cardiovascular
diseases [25-27].
The association of the -786T>C promoter polymorphism
with NOS3 transcriptional levels and the highly signifi-
cant odds ratio (4-fold) for elevated NOS3  levels
(NOS3:B2M > 0.8) and the risk of PCa occurrence are
important evidences of the NOS3 gene promoter role in
the PCa progression. This is further supported by the 2-
fold increase in NOS3 mRNA levels in the positive PCA3
detection class, as demonstrated in Figure 5B. The NOS3
transcriptional activity was also highly correlated with dis-
ease staging (Figure 5A), once its highest level is reached
at the pT2 stage, when the angiogenic stimulus is required
for tumor cell dissemination and metastasis.
Recent studies have described the NO involvement in
many biological processes affecting carcinogenesis [28-
31]. Our results are also supported by previous works
[24], which have also indicated that NOS3  levels may
present a bimodal behavior during cancer development.
The fine mapping of the NOS3 promoter region, flanking
the region -820 to -583, has allowed us to construct four
haplotypes and seven genotypic combinations. We have
found that none of the haplotypes did affect significantly
the  NOS3  levels; in fact, a unique polymorphism (-
786T>C) may be responsible for the NOS3 transcription
regulation, and this polymorphism is observed only in
haplotypes N, C and A.
The increasing NOS3 expression levels associated with the
-786T>C polymorphism may contribute to cancer pro-
gression by providing a selective growth advantage of
tumor cells, by the angiogenic stimulus [6,7] and by caus-BMC Cancer 2008, 8:273 http://www.biomedcentral.com/1471-2407/8/273
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ing DNA damage due to the direct action of O2
- free radi-
cals, as an effect of the excess NO production [8].
The suggestion that decreasing NOS3 expression levels,
which consequently reduce the NO production, would
have an anti-apoptotic role, and may promote tumor
growth [32] may be explained in part by the bimodal
behavior of the NOS3 levels across the stages as shown in
this investigation and in a previous work [24], once lower
levels is mainly seen in advanced tumor stages (pT3 and
pT4).
The first evidence of the association of NOS3 polymor-
phisms with circulating tumor cells was demonstrated
between the intron 4 polymorphism and the folate hydro-
lase – prostate-specific membrane antigen (FOLH1)
expression in the peripheral blood [23]. According to
these authors, patients with the 'a' allele have low plas-
matic NO levels, and therefore are more inclined to have
viable circulating tumor cells.
In this investigation, we did not find association between
the NOS3 gene promoter polymorphisms with circulating
tumor cells PCA3 detection in the peripheral blood, as
shown elsewhere with the 894G>T polymorphism and
the PCA3 detection [24].
The PCA3 gene is a highly specific prostate tumor biomar-
ker that is not found in other kinds of cells and tissues,
whereas its detection on peripheral blood may indicate a
possible metastasis [20]. We believe that the PCA3 is more
specific for tumor detection than the FOLH1  marker,
which presents a high variation on gene expression
among PCa and BPH patients and its utilization as a
biomarker is highly controversial (unpublished data).
In the overall, the PCA3 clinical parameters for PCa cell
detection in the peripheral blood were: 35.0% of sensitiv-
ity (25 out of 71), and 81.0% of specificity (63 out of 78);
however, it is important to observe that a positive result is
not an indication of metastasis and that some BPH cases
may have been misdiagnosed, reducing its true clinical
value.
In fact, the PCA3  detection may become a potential
biomarker for blood diagnosis, once it is exclusively
detected in prostate cancer cells; therefore, patients histo-
logically diagnosed as BPH may probably be tumor con-
fined disease that was missed during biopsy sampling or
by pathological examination. On the other hand, a nega-
tive PCA3 detection in cancer patients may also suggest
that the tumor is organ confined. However, it is important
to emphasize that positive PCA3 detection is not an indi-
cation of faster tumor development or invasiveness.
Prostate cancer is a complex disease due to multifactorial
and multifocal events caused by many biological mecha-
nisms. These mechanisms are represented by differential
gene expression profiles, generating disease developmen-
tal stages that vary from latent to aggressive forms. There-
fore, detection of key genetic alterations at the molecular
level may be a useful tool as a prognostic indicator.
Despite the complexity of events that the NO participates
in many biological processes, its association with carcino-
genesis is critical once NO levels modulate tumor devel-
opment. Part of this differential NO expression is
regulated by NOS3 promoter polymorphisms, specifically
the -786T>C, which may have an influence on the pro-
gression of the disease and not on its occurrence.
There are at least five regulatory elements within the
amplified promoter region (-820 to -583) and their inter-
action with all polymorphisms have not been investi-
gated. Therefore, it is possible that other external and
internal factors may independently influence NOS3 gene
expression masking the true effect of polymorphisms,
which may explain the high variability of NOS3 transcript
levels observed within PCa and BPH groups.
In the present work, higher NOS3  transcript levels in
peripheral blood of positive PCA3 patients than in nega-
tive ones suggest that tumor may be in a medium-late
(pT2) stage of the disease and corroborates with the
molecular approach for disease staging. Therefore, we pro-
pose that patients with differential expression/detection,
such as high NOS3 and negative PCA3 may indicate pT1
stage, while low NOS3 and positive PCA3 may indicate
pT3 or pT4 stages.
Conclusion
In conclusion, this is the first publication that demon-
strates an association of the NOS3 promoter region poly-
morphisms with prostate cancer progression. The strategy
of determining genotypic conformations of the NOS3
promoter region through the SSCP technique demon-
strated to be very effective in genotyping all patients,
which were classified into four haplotypes and seven gen-
otypic conformations. The C allele of the -786T>C poly-
morphism was always associated with at least two other
mutations (haplotypes C, A and N), while the T haplotype
(containing the T allele) had no mutations. Significant rel-
ative risks (> 3 fold) of cancer occurrence were related to
the -786T>C polymorphism, and it is the most important
promoter alteration that may affect the PCa progression,
but not its occurrence. NOS3  transcript relative levels
(NOS3:B2M > 0.8) were 4-fold higher in PCa than in BPH,
and due to its bimodal behavior, the NOS3 levels may be
used as a biomarker together with the PCA3 marker for
molecular staging of the disease.BMC Cancer 2008, 8:273 http://www.biomedcentral.com/1471-2407/8/273
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